Attaining a low disease state — deemed Lupus Low Disease Activity State or LLDAS — has become a major goal for treatment for people with systemic lupus erythematosus. Researchers now have demonstrated that achieving this state not only protects patients from organ damage and improves quality of life,…
A Phase 2a clinical trial evaluating Resolve Therapeutics‘ investigational treatment RSLV-132 in systemic lupus erythematosus (SLE) has completed patient enrollment, the company announced. The trial has recruited 64 patients with active skin disease and are positive for RNA antibodies. Patients were recruited at 20 centers in the United…
Examining gene expression in hair follicles may be sufficient to diagnose chronic discoid lupus erythematosus (CDLE), a kind of lupus in the scalp, avoiding invasive and expensive scalp biopsies, a study suggests. The study, “Plucked hair follicles from patients with chronic discoid lupus erythematosus show a…
Scientists have found a new set of biomarkers that may be used to predict the risk of heart disease in patients with juvenile-onset systemic lupus erythematosus (JSLE). The findings were discussed in an oral presentation titled, “Metabolomics in juvenile-onset SLE: identifying new biomarkers to predict cardiovascular risk,”…
Pregnancy outcomes in women with systemic lupus erythematosus (SLE) have improved significantly in the past two decades, including a marked decrease in maternal mortality, according to a large U.S. study. The research, “Trends in Maternal and Fetal Outcomes Among Pregnant Women With Systemic Lupus Erythematosus in…
An educational self-management program can benefit African-American women with systemic lupus erythematosus (SLE), improving doctor-patient communication and helping patients manage side effects of their medications, a new study suggests. “Health service utilization among African American women living with systemic lupus erythematosus: perceived impacts of a self-management intervention”…
Machine learning analysis strategies can help predict disease status in people with systemic lupus erythematosus (SLE), a study shows. Still, technical variability inherent to each clinical analysis method can represent a roadblock in this process. Fine-tuning of machine learning algorithms and parameter sets may help reduced technical “noise” caused…
How clinical trials into lupus nephritis define their requirements for patient eligibility are too strict, leaving many people with active and severe disease ineligible for participation, according to a study that looked at six lupus trials and how well their “inclusion and exclusion criteria” matched patients in a large U.K.
The Lupus Research Alliance (LRA) and its affiliate Lupus Therapeutics have expanded a collaboration with Bristol-Myers Squibb to help assess the company’s investigational agent BMS-986165 as a possible treatment for lupus nephritis. The candidate’s effectiveness and safety will be evaluated in a global Phase 2 trial (NCT03943147)…
Rituxan (rituximab) can be effective as maintenance therapy for difficult-to-treat patients with systemic lupus erythematosus, allowing them to cut their use of corticosteroids and immunosuppressive agents, a new study says. However, relapses continue to occur frequently, mostly in patients with active joint disease. The study, “Rituximab…